Case Report | Volume: 7, Issue: 10, October, 2017
Case Report | Volume: 7, Issue: 10, October, 2017
Pembrolizumab and procarbazine have been developed as anticancer agents. This study aimed to evaluate the efficacy of the combination of pembrolizumab plus procarbazine in a case with malignant peripheral nerve sheath tumor (MPNST (for the first time. A 48-year-old man referred to the Clinic of Oncology with complaints of constant abdominal pain for a week that the pathology diagnosis showed MPNST. The pathologist reported spindle cell sarcoma (probably dedifferentiated liposarcoma) with a significant PD-L1 expression-tumor proportion score (TPS): 90%. The patient was treated with six courses bi-weekly pembrolizumab combined with procarbazine that after this treatment, abdominopelvic CT scan showed that his lesions completely were resolved. In conclusion, the combination of pembrolizumab with procarbazinecan be a new treatment in the patients with MPNST that in the future studies, the clinicians can check PD-L1 in these patients for better therapeutic aims.
Payandeh M, Sadeghi M, Sadeghi E. Complete Response to Pembrolizumab in a Patient with Malignant Peripheral Nerve Sheath Tumor: The First Case Reported. J App Pharm Sci, 2017; 7 (10): 182-184.
Year
Month